News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,282 Results
Type
Article (8319)
Company Profile (141)
Press Release (476821)
Multimedia
Podcasts (8)
Webinars (6)
Section
Business (167036)
Career Advice (311)
Deals (25791)
Drug Delivery (13)
Drug Development (53081)
Employer Resources (14)
FDA (9804)
Job Trends (8627)
News (238740)
Policy (17961)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (489)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33271)
ALS (104)
Alzheimer's disease (977)
Antibody-drug conjugate (ADC) (313)
Approvals (10415)
Artificial intelligence (327)
ASCO (169)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6995)
BIO (37)
BIOSECURE Act (1)
Biosimilars (111)
BioSpace Insights (19)
Biotechnology (88)
Bladder cancer (142)
Brain cancer (28)
Breast cancer (545)
Cancer (3721)
Cardiovascular disease (222)
Career advice (250)
Career pathing (1)
CAR-T (173)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (48013)
Collaboration (1256)
Commercialization (3)
Compensation (1449)
Complete response letters (37)
COVID-19 (757)
CRISPR (63)
C-suite (740)
Cystic fibrosis (85)
Data (5644)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (342)
Diagnostics (4188)
Digital health (38)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (157)
Drug pricing (12)
Drug shortages (3)
Duchenne muscular dystrophy (164)
Earnings (73736)
Editorial (3)
Employer branding (2)
Employer resources (14)
Events (87656)
Executive appointments (703)
FDA (12427)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (912)
Gene editing (125)
Generative AI (11)
Gene therapy (318)
GLP-1 (294)
Government (951)
Grass and pollen (2)
Guidances (281)
Healthcare (9327)
Hematology (96)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (100)
Immuno-oncology (60)
Indications (156)
Infectious disease (946)
Inflammatory bowel disease (126)
Inflation Reduction Act (5)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12394)
IRA (3)
Job creations (1981)
Job search strategy (240)
JPM (2)
Kidney cancer (17)
Labor market (1)
Layoffs (63)
Legal (5212)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (543)
Lymphoma (250)
Machine learning (28)
Management (3)
Manufacturing (536)
Marketing (8)
MASH (118)
Medical device (8652)
Medtech (8792)
Mergers & acquisitions (14420)
Metabolic disorders (708)
mRNA (54)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (222)
Neuropsychiatric disorders (38)
Neuroscience (1822)
NextGen: Class of 2026 (3157)
Non-profit (847)
Now hiring (15)
Obesity (226)
Opinion (18)
Ovarian cancer (164)
Pain (171)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (502)
Peanut (31)
People (41268)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15490)
Phase 2 (21423)
Phase 3 (14506)
Pipeline (7257)
Policy (20)
Postmarket research (1577)
Preclinical (6544)
Press Release (34)
Prostate cancer (190)
Psychedelics (8)
Radiopharmaceuticals (191)
Rare diseases (574)
Real estate (3025)
Recruiting (6)
Regulatory (14855)
Reports (20)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (49)
Schizophrenia (100)
Series A (153)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Special edition (1)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2028)
Stomach cancer (6)
Supply chain (50)
Tariffs (2)
The Weekly (4)
Vaccines (321)
Venture capital (18)
Weight loss (76)
Women's health (78)
Date
Today (107)
Last 7 days (457)
Last 30 days (1672)
Last 365 days (19215)
2026 (12130)
2025 (19329)
2024 (23078)
2023 (26594)
2022 (34661)
2021 (37216)
2020 (33509)
2019 (23308)
2018 (17489)
2017 (18814)
2016 (17942)
2015 (24290)
2014 (21690)
2013 (18158)
2012 (20249)
2011 (20485)
2010 (20360)
Location
Africa (230)
Alabama (73)
Alaska (2)
Arizona (302)
Arkansas (12)
Asia (18051)
Australia (2116)
California (11918)
Canada (3130)
China (521)
Colorado (483)
Connecticut (407)
Delaware (229)
Europe (24839)
Florida (1782)
Georgia (375)
Hawaii (3)
Idaho (46)
Illinois (699)
India (48)
Indiana (315)
Iowa (14)
Japan (405)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7832)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2626)
New Mexico (12)
New York (2816)
North Carolina (1267)
North Dakota (4)
Northern California (5966)
Ohio (277)
Oklahoma (14)
Oregon (16)
Pennsylvania (2247)
Puerto Rico (20)
Rhode Island (30)
South America (409)
South Carolina (76)
South Dakota (1)
Southern California (4945)
Tennessee (119)
Texas (1925)
United States (38738)
Utah (359)
Vermont (1)
Virginia (152)
Washington D.C. (39)
Washington State (921)
West Virginia (1)
Wisconsin (73)
485,282 Results for "daiichi sankyo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
July 30, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Daiichi Sankyo shares slip after delaying annual earnings report
Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. That same day, the pharma expects to release its five-year business plan.
April 24, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
July 31, 2026
·
8 min read
Antibody-drug conjugate (ADC)
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.
February 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
August 10, 2026
·
6 min read
Press Releases
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
January 22, 2026
·
3 min read
Press Releases
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
May 11, 2026
·
5 min read
Press Releases
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
May 28, 2026
·
13 min read
Earnings
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.
May 11, 2026
·
2 min read
·
Nick Paul Taylor
Antibody-drug conjugate (ADC)
Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
May 20, 2026
·
4 min read
·
Nick Paul Taylor
1 of 48,529
Next
